Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches.

Davis MA, Barnette DA, Flynn NR, Pidugu AS, Swamidass SJ, Boysen G, Miller GP.

Chem Res Toxicol. 2019 Apr 10. doi: 10.1021/acs.chemrestox.9b00006. [Epub ahead of print]

PMID:
30925039
2.

Injury to hypothalamic Sim1 neurons is a common feature of obesity by exposure to high-fat diet in male and female mice.

Nyamugenda E, Trentzsch M, Russell S, Miles T, Boysen G, Phelan KD, Baldini G.

J Neurochem. 2019 Apr;149(1):73-97. doi: 10.1111/jnc.14662. Epub 2019 Feb 11.

PMID:
30615192
3.

Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.

Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ.

Int J Radiat Biol. 2019 Apr;95(4):436-442. doi: 10.1080/09553002.2018.1558299. Epub 2019 Jan 15.

PMID:
30557074
4.

Understanding the importance of low-molecular weight (ethylene oxide- and propylene oxide-induced) DNA adducts and mutations in risk assessment: Insights from 15 years of research and collaborative discussions.

Pottenger LH, Boysen G, Brown K, Cadet J, Fuchs RP, Johnson GE, Swenberg JA.

Environ Mol Mutagen. 2019 Mar;60(2):100-121. doi: 10.1002/em.22248. Epub 2018 Dec 10. Review.

PMID:
30536466
5.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

6.

Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients.

Pouncey DL, Hartman JH, Moore PC, Dillinger DJ, Dickerson KW, Sappington DR, Smith ES 3rd, Boysen G, Miller GP.

Blood Coagul Fibrinolysis. 2018 Nov;29(7):602-612. doi: 10.1097/MBC.0000000000000752.

PMID:
30334816
7.

RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.

Nava Rodrigues D, Casiraghi N, Romanel A, Crespo M, Miranda S, Rescigno P, Figueiredo I, Riisnaes R, Carreira S, Sumanasuriya S, Gasperini P, Sharp A, Mateo J, Makay A, McNair C, Schiewer M, Knudsen K, Boysen G, Demichelis F, de Bono JS.

Clin Cancer Res. 2019 Jan 15;25(2):687-697. doi: 10.1158/1078-0432.CCR-18-2068. Epub 2018 Sep 26.

PMID:
30257982
8.

Response to Interpretation of Mass Spectral Data for the Cisplatin 1,2 Intrastrand Guanine-Guanine Adduct.

Boysen G.

Chem Res Toxicol. 2018 Nov 19;31(11):1108. doi: 10.1021/acs.chemrestox.8b00260. Epub 2018 Oct 16. No abstract available.

PMID:
30215251
9.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

10.

PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.

Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, Bircan E, Gopalan B, Jin J, Patumcharoenpol P, Jenjaroenpun P, Wongsurawat T, Shah N, Boysen G, Ussery D, Nookaew I, Fagan P, Bebek G, Orloff MS.

Front Microbiol. 2018 Aug 6;9:1757. doi: 10.3389/fmicb.2018.01757. eCollection 2018.

11.

Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates.

Sappington D, Helms S, Siegel E, Penney RB, Jeffus S, Bartter T, Bartter T, Boysen G.

Cancer Treat Res Commun. 2018;14:1-6. doi: 10.1016/j.ctarc.2017.08.002. Epub 2017 Aug 19.

PMID:
30104001
12.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
13.

Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches.

Barnette DA, Davis MA, Dang NL, Pidugu AS, Hughes T, Swamidass SJ, Boysen G, Miller GP.

Biochem Pharmacol. 2018 Oct;156:10-21. doi: 10.1016/j.bcp.2018.07.043. Epub 2018 Aug 2.

PMID:
30076845
14.

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira FM, Atkin M, Clarke M, Goodall J, Sharp A, MacDonald T, Rubin MA, Yuan W, Barbieri CE, Carreira S, Mateo J, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5585-5593. doi: 10.1158/1078-0432.CCR-18-0937. Epub 2018 Aug 1.

PMID:
30068710
15.

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez DR, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J.

Clin Colorectal Cancer. 2018 Dec;17(4):280-284. doi: 10.1016/j.clcc.2018.05.011. Epub 2018 Jun 8.

16.

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate SR, Carreira S, Boysen G, Chinnaiyan AM, Swain A, de Bono JS; International SU2C/PCF Prostate Cancer Dream Team.

Clin Cancer Res. 2018 Jul 1;24(13):3149-3162. doi: 10.1158/1078-0432.CCR-17-3571. Epub 2018 Mar 19.

PMID:
29555663
17.

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS.

Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28.

18.

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.

Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnaiyan M, de Bono JS.

Clin Cancer Res. 2017 Oct 15;23(20):6070-6077. doi: 10.1158/1078-0432.CCR-17-0972. Epub 2017 Jul 27. Erratum in: Clin Cancer Res. 2018 May 1;24(9):2234.

19.

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators.

Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.

20.

The Glutathione Conundrum: Stoichiometric Disconnect between Its Formation and Oxidative Stress.

Boysen G.

Chem Res Toxicol. 2017 May 15;30(5):1113-1116. doi: 10.1021/acs.chemrestox.7b00018. Epub 2017 Apr 26. Review.

PMID:
28426193
21.

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.

Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, Wang C, Zhang LZ, Wang Y, Gil V, Aziz S, Christova R, Rodrigues DN, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu DY, de Bono J, Wu H.

Ann Oncol. 2017 Jul 1;28(7):1495-1507. doi: 10.1093/annonc/mdx165.

22.

1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice.

Hartman JH, Miller GP, Caro AA, Byrum SD, Orr LM, Mackintosh SG, Tackett AJ, MacMillan-Crow LA, Hallberg LM, Ameredes BT, Boysen G.

Toxicology. 2017 Mar 1;378:114-124. doi: 10.1016/j.tox.2017.01.005. Epub 2017 Jan 9.

23.

Analysis of DNA methylation in single circulating tumor cells.

Pixberg CF, Raba K, Müller F, Behrens B, Honisch E, Niederacher D, Neubauer H, Fehm T, Goering W, Schulz WA, Flohr P, Boysen G, Lambros M, De Bono JS, Knoefel WT, Sproll C, Stoecklein NH, Neves RPL.

Oncogene. 2017 Jun 8;36(23):3223-3231. doi: 10.1038/onc.2016.480. Epub 2017 Jan 9.

PMID:
28068321
24.

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.

Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31. Review.

25.

The molecular underpinnings of prostate cancer: impacts on management and pathology practice.

Rodrigues DN, Boysen G, Sumanasuriya S, Seed G, Marzo AM, de Bono J.

J Pathol. 2017 Jan;241(2):173-182. doi: 10.1002/path.4826. Epub 2016 Dec 1. Review.

PMID:
27753448
26.
27.

Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines.

Sappington DR, Siegel ER, Hiatt G, Desai A, Penney RB, Jamshidi-Parsian A, Griffin RJ, Boysen G.

Biochim Biophys Acta. 2016 Apr;1860(4):836-43. doi: 10.1016/j.bbagen.2016.01.021. Epub 2016 Jan 26.

28.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

29.

SPOP mutation leads to genomic instability in prostate cancer.

Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, Sboner A, de Bono JS, Demichelis F, Houvras Y, Rubin MA.

Elife. 2015 Sep 16;4. pii: e09207. doi: 10.7554/eLife.09207.

30.

Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).

Hornslien AG, Sandset EC, Igland J, Terént A, Boysen G, Bath PM, Murray GD, Berge E.

Int J Stroke. 2015 Aug;10(6):830-5. doi: 10.1111/ijs.12477. Epub 2015 Mar 22.

PMID:
25808741
31.

In HepG2 cells, coexisting carnitine deficiency masks important indicators of marginal biotin deficiency.

Bogusiewicz A, Boysen G, Mock DM.

J Nutr. 2015 Jan;145(1):32-40. doi: 10.3945/jn.114.201343. Epub 2014 Nov 19.

32.

Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.

Pugh CP, Pouncey DL, Hartman JH, Nshimiyimana R, Desrochers LP, Goodwin TE, Boysen G, Miller GP.

Arch Biochem Biophys. 2014 Dec 15;564:244-53. doi: 10.1016/j.abb.2014.10.006. Epub 2014 Oct 19.

33.

Gendered mental disorders: masculine and feminine stereotypes about mental disorders and their relation to stigma.

Boysen G, Ebersole A, Casner R, Coston N.

J Soc Psychol. 2014 Nov-Dec;154(6):546-65. doi: 10.1080/00224545.2014.953028.

PMID:
25280170
34.

Specific antismoking advice after stroke.

Hornnes N, Larsen K, Brink-Kjær T, Boysen G.

Dan Med J. 2014 Apr;61(4):A4816.

PMID:
24814592
35.

Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity.

Hartman JH, Miller GP, Boysen G.

Toxicology. 2014 Apr 6;318:51-8. doi: 10.1016/j.tox.2014.02.003. Epub 2014 Feb 18.

36.

Simulation of multiple personalities: a review of research comparing diagnosed and simulated dissociative identity disorder.

Boysen GA, VanBergen A.

Clin Psychol Rev. 2014 Feb;34(1):14-28. doi: 10.1016/j.cpr.2013.10.008. Epub 2013 Nov 5. Review.

PMID:
24291657
37.

Differences in butadiene adduct formation between rats and mice not due to selective inhibition of CYP2E1 by butadiene metabolites.

Pianalto KM, Hartman JH, Boysen G, Miller GP.

Toxicol Lett. 2013 Nov 25;223(2):221-7. doi: 10.1016/j.toxlet.2013.08.025. Epub 2013 Sep 8.

38.

A review of dissociative identity disorder research: response to critics.

Boysen GA, Vanbergen A.

J Nerv Ment Dis. 2013 May;201(5):440-3. doi: 10.1097/NMD.0b013e31828e1239. No abstract available.

PMID:
23639896
39.

Punctuated evolution of prostate cancer genomes.

Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA.

Cell. 2013 Apr 25;153(3):666-77. doi: 10.1016/j.cell.2013.03.021.

40.

[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)].

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germanò G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; Comitato per Linee Guida Pratiche (CPG) dell'ESC.

G Ital Cardiol (Rome). 2013 May;14(5):328-92. doi: 10.1714/1264.13964. Italian. No abstract available.

PMID:
23612326
41.

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser A, Kadlubar S.

Drug Metab Dispos. 2013 Apr;41(4):870-7. doi: 10.1124/dmd.112.048157. Epub 2013 Jan 31.

42.

Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.

Kim SY, Kang JY, Hartman JH, Park SH, Jones DR, Yun CH, Boysen G, Miller GP.

Drug Metab Lett. 2012 Sep 1;6(3):157-64.

43.

Cooperative effects for CYP2E1 differ between styrene and its metabolites.

Hartman JH, Boysen G, Miller GP.

Xenobiotica. 2013 Sep;43(9):755-64. doi: 10.3109/00498254.2012.760764. Epub 2013 Jan 18.

44.

A review of published research on adult dissociative identity disorder: 2000-2010.

Boysen GA, VanBergen A.

J Nerv Ment Dis. 2013 Jan;201(1):5-11. doi: 10.1097/NMD.0b013e31827aaf81. Review.

PMID:
23274288
45.

Exposure profiling of reactive compounds in complex mixtures.

Goel S, Evans-Johnson JA, Georgieva NI, Boysen G.

Toxicology. 2013 Nov 16;313(2-3):145-150. doi: 10.1016/j.tox.2012.11.012. Epub 2012 Dec 3.

46.

European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Int J Behav Med. 2012 Dec;19(4):403-88. doi: 10.1007/s12529-012-9242-5. No abstract available.

PMID:
23093473
47.

[European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)].

Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne Mikko, Scholte Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; Avrupa Kardiyoloji Derneği ile Klinik Uygulamada; Kardiyovasküler Hastaliklardan Korunma Üzerinde Çalişan Diğer Derneklerin Beşinci Birleşik Görev Grubu (dokuz derneğin temsilcileri ve davet edilmiş uzmanlardan oluşmaktadir; Avrupa Kardiyovasküler Korunma and Rehabilitasyon (EACPR); özel Katkisi ile geliştirilmiştir.

Turk Kardiyol Dern Ars. 2012 Oct;40 Suppl 3:1-76. Turkish. No abstract available.

48.

Measurement of acylcarnitine substrate to product ratios specific to biotin-dependent carboxylases offers a combination of indicators of biotin status in humans.

Bogusiewicz A, Horvath TD, Stratton SL, Mock DM, Boysen G.

J Nutr. 2012 Sep;142(9):1621-5. doi: 10.3945/jn.112.164814. Epub 2012 Jul 25.

49.

CYP2E1 metabolism of styrene involves allostery.

Hartman JH, Boysen G, Miller GP.

Drug Metab Dispos. 2012 Oct;40(10):1976-83. doi: 10.1124/dmd.112.046698. Epub 2012 Jul 17.

50.

Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Boysen G, Bausch-Fluck D, Thoma CR, Nowicka AM, Stiehl DP, Cima I, Luu VD, von Teichman A, Hermanns T, Sulser T, Ingold-Heppner B, Fankhauser N, Wenger RH, Krek W, Schraml P, Wollscheid B, Moch H.

Neoplasia. 2012 Jun;14(6):535-46.

Supplemental Content

Loading ...
Support Center